Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Gastroenterology. 2017 Feb 14;152(8):1915–1921.e1. doi: 10.1053/j.gastro.2017.02.005

Table 3.

Duration of menopausal hormone therapy and risk of incident fecal incontinence (2008–2012)

Years of hormone use
0 1–5 6–10 >10 Ptrenda.
Person-years of follow up 41,870 40,061 33,455 70,409
No. of cases 1,304 1,501 1,099 2,930
Age-adjusted HR (95% CI) 1.00 1.23 (1.14–1.33) 1.26 (1.16–1.36) 1.36 (1.28–1.45) <0.0001
Multivariate-adjusted HR (95% CI)b. 1.00 1.22 (1.13–1.31) 1.24 (1.15–1.35) 1.32 (1.23–1.41) <0.0001
a

Linear trend estimated by entering duration of use as a continuous variable in the model.

b

Models adjusted for age (months), age at menopause (years), smoking (never, past, current), BMI (<20, 20–24.9, 25–29.9, >30 kg/m2), oral contraceptive use (never, ever), parity (0, 1, 2, ≥3), age at menarche (≤10, 11, 12, 13, ≥14), menopause type (natural, surgical/radiation), ovulatory duration (<24 years, 24–29 years, 29–33 years, ≥34 years), hypertension (yes/no), diabetes mellitus (yes/no), neurologic disease (yes/no), years working night shifts, and history of cholecystectomy (yes/no).